


Highlights of PROVE IT-TIMI 22 results*

Prognostic value of high-precision cardiac troponin serial monitoring

STUDY DESIGN



- Serial monitoring of cTnI can provide additional prognostic information.
- Patients with elevated cTnI or whose cTnI increased over the course of 90 days were at greater risk.



* Prognostic performance of serial high-sensitivity cardiac troponin determination in stable ischemic heart disease: Analysis from PROVE IT-TIMI 22. Presented at 2013 American College of Cardiology (ACC) Annual Scientific Session by Ryan O'Malley, David Morrow, Christopher Cannon, Marc Bonaca, Sabina Murphy, Petr Jarolim, Michael Conrad, Eugene Braunwald and Marc Sabatine.

The Singulex cTnI assay used in the study is for research use only and not intended for diagnostic use.

PROGRESS IN CARDIOVASCULAR DISEASE MANAGEMENT is published by Singulex, Inc. based on publicly available information and is intended for educational purposes only.

Singulex is a registered trademark of Singulex, Inc. © 2013 Singulex, Inc. 97-0085-00

Singulex®